New drug cocktail targets tough lung cancers

NCT ID NCT07253142

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 4 times

Summary

This phase 2 trial tests a combination of two drugs—HLX43 and serplulimab—in 120 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combo can shrink tumors and control the disease. Participants must have cancer that has spread or come back after other treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX43 (a targeted antibody-drug conjugate) combined with serplulimab (an immunotherapy)
What this could lead to: If successful, this could offer a new treatment option for people with advanced lung cancer that hasn't responded to other therapies.
What could go wrong: This is an early phase 2 trial with only 120 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cancer Hospital of Guangzhou Medical University
RECRUITING

Guangzhou, Guangdong, China
Cangzhou People's Hospital
RECRUITING

Cangzhou, Hebei, China
Fujian Cancer Hospital
RECRUITING

Fu'zhou, Fujian, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, China
Hubei Cancer Hospital
RECRUITING

Wuha, Hubei, China
Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
THE Affiliated Hospital of Xuzhou Medical University
RECRUITING

Xuzhou, China
The First Affiliated Hospital of Xinxiang Medical University
RECRUITING

Xinxiang, Henan, China
The People's Hospital of Guangxi Zhuangzu Autonomous Region
RECRUITING

Nanning, Guangxi, 530016, China
The Second Hospital of Anhui Medical University
RECRUITING

Hefei, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.